Drug Profile
Research programme: antibacterials - ImmuPharma
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator ImmuPharma
- Developer CNRS; ImmuPharma
- Class Peptides
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in France (IV)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Nosocomial-infections in France (IV)
- 06 Apr 2020 Research programme for antibacterials is still in preclinical trials for Nosocomial infections and Methicillin-resistant Staphylococcus aureus infections in France